PLUR

distress 3/10 · well-funded / low risk

$1.85-5%today-67% from 52w high

pluri-biotech.com127 employeesFounded 2001Haifa, IsraelBiotechnology

Revenue

pre-revenue

Liquidity

$47M

Runway

2.6 yrs

Shares 1y

+32%

Price & events

-43.8% over 6M

CatalystRating changeDilutionFinancingdashed = today

-5.1%

+5.7%

-8.4%

-44.8%

-43.8%

-63.1%

-67.0%

-93.4%

-96.7%

All

Overview

Market Cap: $19.96M
Volume: 27.90K
52 Week Range: $1.63 – $5.68
Total Shares: 10.79M
Float Shares: 4.63M
Short %: 0.76%
% Held by Insiders: 46.57%
% Held by Institutions: 12.55%
RVOL: 0.79x
Beta: 0.63

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 4

2025-04-28partnershipCompleted acquisition of approximately 71% equity in Kokomodo Ltd. for $4.5 million payable in Common Shares.SEC 8-K
2025-04-15trial discontinuedPLX-R18 · NIAID terminated the contract for development of PLX-R18 for Hematopoietic Acute Radiation Syndrome for convenience.SEC 8-K
2024-09-26fda agreementNasdaq confirmed Pluri regained compliance with stockholders' equity requirement.SEC 8-K
2024-07-08partnershipProof of concept agreement with leading international agriculture corporation to boost vegetable supply using Pluri's 3D cell expansion technologySEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 10,789,546 · 0 offerings/1y · 2 PIPEs

2026-06-228-Kmaterial_agreement
2026-03-278-Kprivate_placement
2025-12-098-Kprivate_placement
2025-09-25EFFECTshelf_effective
2025-09-17S-3shelf_registration
2025-04-258-Kprivate_placement
2025-03-138-Kprivate_placement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2025-06-02Alliance Global PartnersBuy

Competitors

none identified